Enanta Pharmaceuticals (ENTA)
(Real Time Quote from BATS)
$12.56 USD
-0.05 (-0.40%)
Updated Aug 14, 2024 09:48 AM ET
3-Hold of 5 3
F Value D Growth A Momentum D VGM
Brokerage Reports
Enanta Pharmaceuticals, Inc. [ENTA]
Reports for Purchase
Showing records 1 - 20 ( 164 total )
Company: Enanta Pharmaceuticals, Inc.
Industry: Medical - Drugs
1Q Recap: Approaching Two Key Data Readouts From Enanta''s RSV Franchise in 2H24; PT to $27 on Higher OpEx
Provider: H.C. Wainwright & Co., Inc.
Analyst: ARCE E
Company: Enanta Pharmaceuticals, Inc.
Industry: Medical - Drugs
FY1Q24 Recap; Approaching Key Quarter in 3Q24 With at Least Two Data Readouts From Its RSV Programs
Provider: H.C. Wainwright & Co., Inc.
Analyst: ARCE E
Company: Enanta Pharmaceuticals, Inc.
Industry: Medical - Drugs
RSV Program Top-line Readouts On Target in 3Q24; Enanta Reveals New Immunology Program; Affirm Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: ARCE E
Company: Enanta Pharmaceuticals, Inc.
Industry: Medical - Drugs
Optimized Entry and Exit Levels for ENTA 112123
Provider: Stock Traders Daily
Analyst: Research Department
Company: Enanta Pharmaceuticals, Inc.
Industry: Medical - Drugs
FY4Q23 Recap; EDP-323 RSV Challenge Study Initiated; 3Q24 Readouts to Inform RSV Program''s Path Forward; Affirm Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: ARCE E
Company: Enanta Pharmaceuticals, Inc.
Industry: Medical - Drugs
Taking a Deep Dive On The Significant Unmet Need in RSV; Reduce PT to $30 Following Model Updates
Provider: H.C. Wainwright & Co., Inc.
Analyst: ARCE E
Company: Enanta Pharmaceuticals, Inc.
Industry: Medical - Drugs
EDP-323 Data Presentation at ESWI Influenza Conference Sets the Stage For Phase 2 Challenge Study; Affirm Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: ARCE E
Company: Enanta Pharmaceuticals, Inc.
Industry: Medical - Drugs
F3Q23 Recap; EDP-323 Advances Into RSV Challenge Study in Early 4Q23; First Data Expected in 2Q24; Affirm Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: ARCE E
Company: Enanta Pharmaceuticals, Inc.
Industry: Medical - Drugs
Phase 1 Dataset Supports EDP-323''s Advancement Into Human Challenge Study For RSV by Early 4Q23; Affirm Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: ARCE E
Company: Enanta Pharmaceuticals, Inc.
Industry: Medical - Drugs
FY2Q23 Recap; EDP-235 Improved Symptoms But No Virologic Effect Observed; EDP-323 Data Expected in June; Affirm Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: ARCE E
Company: Enanta Pharmaceuticals, Inc.
Industry: Medical - Drugs
ICAR 2023: Two Presentations in Our Coverage Universe Provide Early Datasets in COVID-19
Provider: H.C. Wainwright & Co., Inc.
Analyst: ARCE E
Company: Enanta Pharmaceuticals, Inc.
Industry: Medical - Drugs
FY1Q23 Recap; SPRINT Data Expected in May; Positive Results to Support Phase 3 in 2H23; Raising PT to $68; Affirm Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: ARCE E
Company: Enanta Pharmaceuticals, Inc.
Industry: Medical - Drugs
Two Data Readouts From COVID-19 and RSV Programs in 1H23; New Research Programs Expand Pipeline; Affirm Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: ARCE E
Company: Enanta Pharmaceuticals, Inc.
Industry: Medical - Drugs
Looking for a Second Act; We See Value in the RSV Program; Initiate Buy, $56 PT
Provider: H.C. Wainwright & Co., Inc.
Analyst: ARCE E
Company: Enanta Pharmaceuticals, Inc.
Industry: Medical - Drugs
Healthcare Coverage Update - Dropping Coverage
Provider: Roth Capital Partners, Inc.
Analyst: Research Department
Company: Enanta Pharmaceuticals, Inc.
Industry: Medical - Drugs
Company: Enanta Pharmaceuticals, Inc.
Industry: Medical - Drugs
Company: Enanta Pharmaceuticals, Inc.
Industry: Medical - Drugs
RSV Study Hints Again at Efficacy, but Misses Primary Endpoint
Provider: Roth Capital Partners, Inc.
Analyst: JALLAH Z